TWD 37.4
(5.65%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 31.04 Million TWD | -59.13% |
2022 | 72.14 Million TWD | 14.41% |
2021 | 63.06 Million TWD | 298.39% |
2020 | -31.78 Million TWD | -47.46% |
2019 | -21.55 Million TWD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 10.15 Million TWD | -11.24% |
2024 Q2 | -331 Thousand TWD | -103.26% |
2023 Q4 | 11.44 Million TWD | 555.59% |
2023 FY | - TWD | -59.13% |
2023 Q3 | 1.74 Million TWD | -81.36% |
2023 Q2 | 9.36 Million TWD | 10.18% |
2023 Q1 | 8.49 Million TWD | -54.95% |
2022 FY | - TWD | 14.41% |
2022 Q4 | 18.86 Million TWD | 0.0% |
2021 FY | - TWD | 298.39% |
2020 FY | - TWD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Allied Biotech Corporation | 204.79 Million TWD | 84.839% |
GeneFerm Biotechnology Co., Ltd. | 231.09 Million TWD | 86.565% |
Easywell Biomedicals, Inc. | -85.5 Million TWD | 136.313% |
TTY Biopharm Company Limited | 1.52 Billion TWD | 97.963% |
Synmosa Biopharma Corporation | 1 Billion TWD | 96.922% |
Orient EuroPharma Co., Ltd. | 582.93 Million TWD | 94.674% |
Center Laboratories, Inc. | -175.17 Million TWD | 117.724% |
Orient Pharma Co., Ltd. | 172.39 Million TWD | 81.99% |
InnoPharmax Inc. | -62.12 Million TWD | 149.981% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 126.67 Million TWD | 75.491% |
Excelsior Biopharma Inc. | -29.36 Million TWD | 205.717% |
DV Biomed Co., Ltd. | 407.64 Million TWD | 92.383% |
Foresee Pharmaceuticals Co., Ltd. | -912.16 Million TWD | 103.404% |
Handa Pharmaceuticals, Inc. | 802.78 Million TWD | 96.132% |
UniPharma Co., Ltd. | -16.25 Million TWD | 291.018% |
Anxo Pharmaceutical Co., Ltd. | 131.31 Million TWD | 76.355% |
Alar Pharmaceuticals Inc. | 394.52 Million TWD | 92.13% |
Winston Medical Supply Co., Ltd. | 228.32 Million TWD | 86.402% |
Mercury Biopharmaceutical Corporation | -39.03 Million TWD | 179.541% |
Bioray Biotech Co., Ltd | 12.13 Million TWD | -155.855% |
TSH Biopharm Corporation Limited | 99.35 Million TWD | 68.749% |